Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- 22-gauge;; 25-gauge;; core;; endoscopic ultrasound;; fine-needle aspiration;; pancreas;; trucut biopsy;; randomized-trial;; mass lesions;; eus-fna;; accuracy;; improve;; Gastroenterology & Hepatology (1)
- Adverse drug reactions;; Crohn's disease;; Drug induced liver injury;; Hepatotoxicity;; Inflammatory bowel disease;; Ulcerative colitis (1)
- Crohn’s disease;; Fistulas;; Inflammatory bowel disease;; Opiates;; Smoking (1)
- Inflammation;; mucosal healing;; remission;; immunomodulator drugs;; infliximab;; ulcerative colitis;; inflammatory bowel diseases;; crohns-disease;; induction therapy;; anti-tnf;; adalimumab;; infliximab;; integrin;; lymphoma;; trial;; ibd;; Health Care Sciences & Services (1)
- PillCam SB2;; Capsule endoscopy;; Obscure gastrointestinal bleeding;; single-center experience;; pillcam sb;; multicenter;; completion;; Gastroenterology & Hepatology (1)
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Patient Considerations In The Management Of Ulcerative Colitis - Role Of Vedolizumab, M. Kothari, P. Mudireddy, A. Swaminath
Patient Considerations In The Management Of Ulcerative Colitis - Role Of Vedolizumab, M. Kothari, P. Mudireddy, A. Swaminath
Journal Articles
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6-24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn's disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific …
Hepatic Manifestations Of Non-Steroidal Inflammatory Bowel Disease Therapy, R. Hirten, K. Sultan, A. Thomas, D. E. Bernstein
Hepatic Manifestations Of Non-Steroidal Inflammatory Bowel Disease Therapy, R. Hirten, K. Sultan, A. Thomas, D. E. Bernstein
Journal Articles
Inflammatory bowel disease (IBD) is composed of Crohn's disease and ulcerative colitis and is manifested by both bowel-related and extraintestinal manifestations. Recently the number of therapeutic options available to treat IBD has dramatically increased, with each new medication having its own mechanism of action and side effect profile. A complete understanding of the hepatotoxicity of these medications is important in order to distinguish these complications from the hepatic manifestations of IBD. This review seeks to evaluate the hepatobiliary complications of non-steroid based IBD medications and aide providers in the recognition and management of these side-effects.
Comparison Of The Diagnostic Yield And Outcomes Between Standard 8 H Capsule Endoscopy And The New 12 H Capsule Endoscopy For Investigating Small Bowel Pathology, M. Rahman, S. Akerman, B. Devito, L. Miller, M. Akerman, K. Sultan
Comparison Of The Diagnostic Yield And Outcomes Between Standard 8 H Capsule Endoscopy And The New 12 H Capsule Endoscopy For Investigating Small Bowel Pathology, M. Rahman, S. Akerman, B. Devito, L. Miller, M. Akerman, K. Sultan
Journal Articles
AIM: To evaluate the completion rate and diagnostic yield of the PillCam SB2-ex in comparison to the PillCam SB2. METHODS: Two hundred cases using the 8-h PillCam SB2 were retrospectively compared to 200 cases using the 12 h PillCam SB2-ex at a tertiary academic center. Endoscopically placed capsules were excluded from the study. Demographic information, indications for capsule endoscopy, capsule type, study length, completion of exam, clinically significant findings, timestamp of most distant finding, and significant findings beyond 8 h were recorded. RESULTS: The 8 and 12 h capsule groups were well matched respectively for both age (70.90 +/- 14.19 …
Comparison Of Endoscopic Ultrasound Guided 22-Gauge Core Needle With Standard 25-Gauge Fine-Needle Aspiration For Diagnosing Solid Pancreatic Lesions, M. Berzosa, N. Villa, H. B. El-Serag, D. V. Sejpal, K. K. Patel
Comparison Of Endoscopic Ultrasound Guided 22-Gauge Core Needle With Standard 25-Gauge Fine-Needle Aspiration For Diagnosing Solid Pancreatic Lesions, M. Berzosa, N. Villa, H. B. El-Serag, D. V. Sejpal, K. K. Patel
Journal Articles
Background and Objectives: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the standard modality for diagnosing pancreatic masses. We compared the diagnostic yield of a new EUS-guided 22-gauge core needle biopsy to a standard 25-gauge FNA in sampling the same pancreatic lesions during the same EUS. Patients and Methods: The main outcomes of the study were the sample adequacy of each method to provide a final pathological diagnosis, and the concordance in diagnosis between core and FNA specimens. The secondary outcomes were the sensitivity and specificity of the findings for each needle and the incremental yield of using both needles compared with …
Clinical Markers Of Crohn's Disease Severity And Their Association With Opiate Use, M. Cheung, S. Khan, M. Akerman, C. K. Hung, K. Vennard, N. Hristis, K. Sultan
Clinical Markers Of Crohn's Disease Severity And Their Association With Opiate Use, M. Cheung, S. Khan, M. Akerman, C. K. Hung, K. Vennard, N. Hristis, K. Sultan
Journal Articles
BACKGROUND: The safety of opiate use for patients with Crohn's disease (CD) has long been a concern. The recent Crohn's therapy, resource, evaluation, and assessment tool (TREAT) registry update has added to these concerns by demonstrating an association of opiate use with an increased risk of infection and death in CD. While the association is clear, the relationship of opiates to these negative outcomes is not. It is unknown whether opiates are a contributing factor to these negative outcomes or if their use is merely a marker of more severe disease. We hypothesized that opiate use is not harmful in …